Can Genzyme Lower the Ante in Discovery?
Genzyme's added what it hopes will be a lower-cost discovery operation to its product-focused business. It's using tracking stock to keep the expenses off Genzyme Corp.'s P&L, and a pragmatic research approach that won't bet everything on a single technological direction. So far the market's not convinced.
You may also be interested in...
Progress for two US-based companies in the race to develop a COVID-19 vaccine.
BeiGene's BTK inhibitor for leukemia/lymphoma and Sanofi/Genzyme's enzyme replacement therapy for MPS I among novel drugs newly approved in China.
A new document from the US FDA details acceptable substitutions for COVID-19 testing components that may be difficult to come by. See what the regulatory agency said about it here.